The use of felbamate to treat infantile spasms
1Department of Neurology, Texas Tech University School of Medicine, Lubbock, USA.
Insights
Felbamate effectively resolved infantile spasms in three of four infants who previously failed other treatments. Further controlled studies are needed to confirm felbamate
Area of Science:
- Pediatric Neurology
- Epileptology
- Pharmacology
Background:
- Infantile spasms (IS) are a severe epilepsy syndrome in infants.
- Tuberous sclerosis is one etiology of IS.
- Conventional therapies for IS often fail.
Observation:
- Felbamate was initially successful in an infant with tuberous sclerosis and IS.
- Three additional infants with IS and different etiologies were treated with felbamate after failing other therapies.
Findings:
- Three of four infants experienced complete resolution of infantile spasms within one week of felbamate treatment.
- One patient showed initial improvement but not long-term response.
- Felbamate appears promising for treating infantile spasms.
Implications:
- Felbamate may be a viable treatment option for refractory infantile spasms.
- Further controlled clinical trials are necessary to establish safety and efficacy.
- The potential progression of IS to Lennox-Gastaut syndrome, for which felbamate is approved, supports its consideration in IS management.
Abstract:
Based on the initial successful use of felbamate for infantile spasms in an infant with tuberous sclerosis, three additional infants with infantile spasms of different etiologies who had failed conventional therapies were treated with felbamate. Three of the four patients have shown complete resolution of infantile spasms. All responding patients did so within 1 week of starting felbamate. The one treatment failure had an initial reduction of seizure frequency and severity but has not maintained that response long term. Controlled studies are needed to firmly establish that felbamate is both safe and effective for the treatment of infantile spasms. As these cases document, felbamate is currently available for use in infantile spasms, and the frequent conversion of infantile spasms to Lennox-Gastaut syndrome, for which felbamate is approved, makes its use in infantile spasms logical.
Related Concept Videos
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Skeletal Muscle Relaxants: Therapeutic Uses
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


